It’s estimated around 20% of patients will discontinue their first course of anti–tumor necrosis factor-α (anti–TNF-α) and rates increase over time
Results of a recent systematic literature review suggest the need to standardize management of anti–tumor necrosis factor-α (anti–TNF-α) failure in patients with psoriasis and reflect the incorporation of new targets like interleukin (IL) inhibitors in the treatment sequence.
Findings were published in Annals of Medicine.
As therapeutic options for moderate to severe psoriasis have increased significantly in recent years, choosing the appropriate treatment option for each patient can be a challenge, authors explained.
“More recently, the availability of anti–TNF-α biosimilars has provided a less costly alternative to their precursors, facilitating the access to anti–TNF-α as a first-line biologic treatment for moderate to severe plaque psoriasis,” they added.
However, around 20% of patients discontinue their first course of anti–TNF-α and discontinuation rates rise over time. This is due in large part to a failure to respond to treatment. It’s also difficult to predict or determine patients’ response to anti–TNF-α in routine practice.
To gather information on the criteria used to define treatment failure, the researchers carried out a systematic literature review.
Fifty-eight publications were included in the review, of which 37 (63.8%) described the criteria used to define anti–TNF-α primary or secondary failure. The studies were gleaned from international and Spanish national databases.
Analyses revealed:
Most studies also failed to consider patient-reported outcomes when assessing psoriasis treatment efficacy, the authors said, a finding “which contrasts with recent recommendations on the inclusion of patient-reported [health-related quality of life] as a supporting criterion when considering clinical outcomes.”
Reasons for anti–TNF-α discontinuation varied among studies, and efficacy and safety-related issues were the most common. However, results suggest other factors like patients’ preferences should be considered, authors said.
Of the 58 included studies, the majority were observational studies, 16 were clinical trials, 3 were clinical practice guidelines, and 1 corresponded to a narrative review. Twenty-three observational studies had a retrospective design and the rest had a prospective design. The authors applied the 30-point Consolidated Standards of Reporting Trials statement for randomized clinical trials included in the review.
Researchers also noted the predominance of PASI 50 in the included studies implies stricter criteria, like the PASI 75, were underused. Less than 20% of studies used the strictest criteria, PASI9 0 or Physician’s Global Assessment 0 or 1.
“Both criteria are equivalent and show a ‘clear’ or ‘almost clear’ disease status and have traditionally been considered too stringent to define treatment response,” the authors wrote.
Only English and Spanish publications were included in the current review, marking a limitation. In addition, because treatment options for psoriasis continue to increase rapidly, validity of the results outlined could be limited in time, the researchers noted. No biosimilars were included in the studies.
Overall, “the appraised evidence illustrates significant heterogeneity in the criteria used to define anti–TNF-α failure,” the authors concluded.
“Although the recommendations on which treatment to choose after anti–TNF-α failure are scarce, our findings reflect a pattern in the last 10 years, with greater incorporation of new targets, mainly IL inhibitors such as IL-12/IL-23, IL-17, and IL-23 inhibitors in the treatment sequence for moderate to severe psoriasis patients,” they said.
Reference
Romero IB, Puchades AM, Pibernat MR, Genao DPR, de la Cueva Dobao P, Carrascosa JM. Criteria used to define tumor necrosis factor-alpha inhibitors failure in patients with moderate-to-severe psoriasis: a systematic literature review. Ann Med. Published online April 4, 2023. doi:10.1080/07853890.2023.2192957
Persistence Pays Off With Zanubrutinib: A Challenging CLL Case With a Prior BTK Inhibitor Failure
May 10th 2024The case of a 77-year-old woman with a long chronic lymphocytic leukemia (CLL) history illustrates the novel use of zanubrutinib as a potential option for some patients who have failed first-generation Bruton tyrosine kinase (BTK) inhibitors and venetoclax.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Posters Characterize DMD Caregiver Experiences, Impact of Gene Therapy on Caregiving Demands
May 10th 2024Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.
Read More